The global hepatic encephalopathy market is witnessing strong growth with an increasing number of a clinical study for liver cirrhosis

 An increasing number of clinical trials for the development of new therapeutic products for liver diseases are propelling the growth of the global hepatic encephalopathy market. For instance, in December 2019, Kaleido Biosciences, Inc., a clinical-stage healthcare company announced positive results from a proof-of-concept clinical study, in which they used KB174, a novel microbiome metabolic therapy (MMT) in combination with a 15N-labeled tracer, a biomarker of microbiome ammonia production, in patients with liver cirrhosis. The treatment reduced the 15N urinary output and was well tolerated among the patients. The increasing prevalence of liver disease is also expected to propel the growth of the hepatic encephalopathy market. According to the National Library of Medicine, liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due to complications of cirrhosis and 1million due to viral hepatitis and hepatocellular carcinoma.

https://www.coherentmarketinsights.com/market-insight/hepatic-encephalopathy-market-2596


Europe is expected to lead the global hepatic encephalopathy market, due to the increase in the research and development activities for the treatment and management of liver diseases. For instance, in 2019, ALIVER, a research and awareness project from the European Union's Horizon 2020 research and innovation program received funding of US$ 8.5 million for the project. ALIVER consortium developed a novel and innovative liver dialysis machine that will help the liver to naturally regenerate and to keep patients alive and healthy until a liver donor is available.

Major players engaged in the global hepatic encephalopathy market\ are ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd... Read more

Post a Comment

Previous Post Next Post